Growing occurrences of type I and II diabetes are
anticipated to drive the Asia-Pacific insulin market over the forecast period
(from 2012 to 2020). Insulin is basically a peptide hormone released using beta
cells by the pancreas. Its major function is to allow the absorption of glucose
in the body from the blood, which in turn provides energy and stabilizes the
blood glucose levels. Lifestyle changes and unhealthy eating habits are common
factors that lead to diabetes nowadays. In addition to this, high rates of
destruction of beta cells and hypertension are also major causes of diabetes.
Moreover, factors that drive the industry are growing
geriatric population base and surging demand for insulin analogs &
minimally invasive & noninvasive therapies for diabetes. Greater
availability of safety syringes and pen needles can also boost the Asia-Pacific
insulin market in the years to come. Both private & public firms
participate actively in suppressing and controlling diabetes by investing huge
funds in research and development. Various emerging countries offer a huge
market potential for insulin. Product demand in these regions can significantly
add to overall revenues and industry shares.
The advent of minimally invasive diagnostic treatments
has created a large gap between the supply and demand of insulin to control
blood glucose levels. Tremendous government support, such as subsidies &
grants to insulin-manufacturing pharmacies may boost demand over the next few
years. However, high costs of production and manufacturing complexities may
negatively impact the industry. Growing target population base and greater
awareness among patients about various treatment options for diabetes can boost
product demand.
The Asia-Pacific insulin market is categorized as per
products and regions. According to products, the segments are pre-mixed
insulin, intermediate acting, rapid acting, long acting, and short acting. In
2013, the market for immediate-acting insulin & long acting insulin held
more than 50% industry shares in terms of revenue. Owing to quick results in
balancing blood sugar levels, immediate-acting insulin can witness lucrative
growth in the near future. Apart from this, immediate-acting insulin is also
widely being accepted by a number of medical practitioners in clinics &
hospitals.
Long-acting insulin is anticipated to grow considerably
during the forecast period. This type of insulin helps stabilize blood glucose
levels for a few weeks at a stretch. This is a very efficient & popular
method for controlling diabetes. It also exhibits long lasting effects.
However, the doses can vary from person to person depending upon their specific
needs. For instance, a doctor prescribes insulin dosage to his patient
considering the latter’s age, consumption of junk foods, insulin production
rate, levels of blood glucose, and even his consumption of alcohol.
Geographically, the Asia-Pacific insulin industry is
categorized into China, Brazil, India, South Korea, Australia, and other
developing nations. Regional drivers are growing geriatric population and
heightened awareness among people about diabetes & its treatments. Steady
improvements in healthcare infrastructure and the availability of innovative
technologies can boost the market in the coming years.
